Most Read Articles
Jairia Dela Cruz, 14 Jan 2019
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
01 Mar 2016
Bathing with 2% chlorhexidine gluconate-medicated washcloth is cost-effective for the prevention of central line-associated bloodstream infection (CLABSI), based on a systematic review and meta-analysis of four studies.
08 Jan 2019
Treatment with spironolactone has shown consistent, albeit modest, clinical effectiveness in older patients with heart failure with reduced ejection fraction (HFrEF) regardless of renal eligibility criteria used, a recent study has shown.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Adalimumab feasible for long-term control of hidradenitis suppurativa

22 Dec 2018

Continuous weekly administration of adalimumab (ADA) at 40 mg appears to be an adequate option for long-term control of moderate-to-severe hidradenitis suppurativa (HS), a recent study has shown.

Eighty-eight study participants were given ADA (median age 35.5 years; 63.6 percent female) of whom 63 either achieved HS clinical response (HiSCR) at week 12 or showed a 25-percent reduction in abscess and inflammatory nodule (AN) counts relative to baseline (responders plus partial responders [PRR]; median age 36.0 years; 65.1 percent female).

Results were generally persistent over time. The percentage of ADA-treated patients achieving HiSCR increased from 52.3 percent at week 12 to 62.5 percent at week 36. By week 168, this proportion was back down to 52.3 percent.

Similarly, there were improvements persistent over time in the counts of AN, draining fistula, inflammatory nodules and total fistula in both groups. The same was true for pain rating. The rate of flare was low and stable.

There was also a meaningful improvement in Dermatology Life Quality Index scores in both groups, which was maintained through week 72.

In terms of treatment safety, no adverse events of opportunistic infections were seen, except for oral candidiasis, over the mean exposure duration of 2.21 and 2.26 patient-years in the ADA-treated and PRR groups, respectively. Three serious infections were reported overall, with one case of pneumonia being probably related to the treatment.

The most common treatment-emergent adverse events included hidradenitis, headaches, upper respiratory tract infections, arthralgia, diarrhoea and dizziness, among others.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 14 Jan 2019
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
01 Mar 2016
Bathing with 2% chlorhexidine gluconate-medicated washcloth is cost-effective for the prevention of central line-associated bloodstream infection (CLABSI), based on a systematic review and meta-analysis of four studies.
08 Jan 2019
Treatment with spironolactone has shown consistent, albeit modest, clinical effectiveness in older patients with heart failure with reduced ejection fraction (HFrEF) regardless of renal eligibility criteria used, a recent study has shown.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.